Ann Lab Med.  2012 Nov;32(6):452-454.

Rare Frameshift Mutation Cys475Tyrfs*11 in the BCR/ABL Kinase Domain Contributes to Imatinib Mesylate Resistance in 2 Korean Patients with Chronic Myelogenous Leukemia

Affiliations
  • 1Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea. hschi@amc.seoul.kr

Abstract

No abstract available.


MeSH Terms

Adult
Antineoplastic Agents/therapeutic use
Asian Continental Ancestry Group/*genetics
Base Sequence
Benzamides/therapeutic use
Drug Resistance, Neoplasm
Female
Frameshift Mutation
Fusion Proteins, bcr-abl/*genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/drug therapy/*genetics
Male
Piperazines/therapeutic use
Pyrimidines/therapeutic use
Republic of Korea
Sequence Analysis, DNA
Young Adult
Antineoplastic Agents
Benzamides
Fusion Proteins, bcr-abl
Piperazines
Pyrimidines
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr